Document is current

Article History

Received: 1 March 2024

Accepted: 15 August 2024

First Online: 5 September 2024

Declarations

:

: N/A

: N/A

: The authors declare the following potential conflicts of interest. BC has received honoraria/funding from Alexion, Amgen, Kyowa Kirin, Novartis, Theramex, UCB, Viatris and Alexion. He has served as an expert in advisory board meetings for UCB. NG has received honoraria from Amgen, Theramex, Gedeon-Richter and UCB. MLB has received grants from Abiogen, Alexion, Amgen, Amolyt, Amorphical, Bruno Farmaceutici, CoGeDi, Echolight, Eli Lilly, Enterabio, Gedeon Richter, Italfarmaco, Kyowa Kirin, Menarini, Monte Rosa Therapeutics, SPA, Takeda, Theramex and UCB. She received consulting fees from Aboca, Alexion, Amolyt, Bruno Farmaceutici, Calcilytix, Echolight, Kyowa Kirin, Personal Genomics and Smoke Free World Foundation. She also received honoraria from Amgen, Bruno Farmaceutici, Calcilytix, Kyowa Kirin and UCB. HS received honoraria/funding from UCB, Amgen, Theramex, Gedeon Richter and Stadapharm and is a member of the DVO guideline group and a board member of the European Society of Calcified Tissues.